Research graph
References from Cost-effectiveness of respiratory syncytial virus prevention strategies in Mozambique: a modelling study. Local targets link to admitted publications; unresolved targets remain external evidence.
Vaccine investment strategy
External reference
Inquérito Demográfico e de Saúde em Moçambique 2022–23. Relatório definitivo
2024 · External reference
methods for the economic Evaluation of Health Care Programmes
2015 · External reference
ProVac Toolkit - PAHO/WHO | Pan American Health Organization
External reference
Cost-effectiveness of pharmaceutical strategies to prevent respiratory syncytial virus disease in young children: a decision-support model for use in low-income and middle-income countries
10.1186/s12916-023-02827-5 · 2023 · External reference
Cost-Effectiveness of Respiratory Syncytial Virus Preventive Interventions in Children: A Model Comparison Study
10.1016/j.jval.2022.11.014 · 2023 · External reference
WHO preferred product characteristics of monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease
2021 · External reference
Palivizumab for the prevention of respiratory syncytial virus infection
2010 · External reference
Making choices in health: WHO guide to cost-effectiveness analysis
2003 · External reference
Cost–effectiveness thresholds: pros and cons
10.2471/blt.15.164418 · 2016 · External reference
Respiratory Syncytial Virus (RSV) disease
2023 · External reference
Cost per DALY averted thresholds for low- and middle-income countries: evidence from cross country data
2015 · External reference
GDP per capita (current US$) - Mozambique | Data
2022 · External reference
Immunization Data
2024 · External reference
Deaths Attributed to Respiratory Syncytial Virus in Young Children in High–Mortality Rate Settings: Report from Child Health and Mortality Prevention Surveillance (CHAMPS)
10.1093/cid/ciab509 · 2021 · External reference
The burden of RSV-associated illness in children aged < 5 years, South Africa, 2011 to 2016
10.1186/s12916-023-02853-3 · 2023 · External reference
Infant deaths from respiratory syncytial virus in Lusaka, Zambia from the ZPRIME study: a 3-year, systematic, post-mortem surveillance project
10.1016/s2214-109x(21)00518-0 · 2022 · External reference
World Population Prospects - Population Division - United Nations
2024 · External reference
Estimating the Economic Burden of Respiratory Syncytial Virus Infection among children under 2 years of age receiving care in Maputo, Mozambique
10.7189/jogh.15.04076 · External reference
Age distribution of respiratory syncytial virus disease in children <5 years of age in low-income and middle-income countries: a systematic review and meta-analysis
External reference
Mozambique: WHO and UNICEF estimates of immunization coverage: 2022 revision
2023 · External reference
Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis
10.1016/s0140-6736(22)00478-0 · 2022 · External reference
Vaccination and Immunization Statistics
2024 · External reference
Moçambique Inquérito Demográfico e de Saúde, 2011
2011 · External reference
The economic burden of RSV-associated illness in children aged < 5 years, South Africa 2011–2016
10.1186/s12916-023-02854-2 · 2023 · External reference
Impact and cost-effectiveness of potential interventions against infant respiratory syncytial virus (RSV) in 131 low-income and middle-income countries using a static cohort model
10.1136/bmjopen-2020-046563 · 2021 · External reference
Estimating the cost-effectiveness of maternal vaccination and monoclonal antibodies for respiratory syncytial virus in Kenya and South Africa
10.1186/s12916-023-02806-w · 2023 · External reference
Respiratory syncytial virus vaccines: the future is bright
10.1016/s2213-2600(24)00184-x · 2024 · External reference
Mozambique’s grand plan to reach more than 750,000 unimmunised children in 2024
External reference
Cost-effectiveness of rotavirus vaccination in Mozambique
10.1016/j.vaccine.2022.07.044 · 2022 · External reference
How will climate change impact Mozambique?
2023 · External reference
Climate change could make RSV respiratory infection outbreaks less severe, more common
2024 · External reference
Mozambique: Under-five mortality rate - Total
2023 · External reference
Epidemic dynamics of respiratory syncytial virus in current and future climates
10.1038/s41467-019-13562-y · 2019 · External reference
Climatic drivers of seasonal dynamics for Respiratory Syncytial Virus (RSV) in Antananarivo, Madagascar, 2011-2021 | medRxiv
10.1101/2024.02.03.24302203v1 · External reference
RSV Prefusion F Protein–Based Maternal Vaccine — Preterm Birth and Other Outcomes
10.1056/nejmoa2305478 · 2024 · External reference
Influenza: NICD recommendations for the diagnosis, management, prevention and public health response
2024 · External reference
Respiratory Syncytial Virus Infection (RSV)
2024 · External reference
Immunisation
2024 · External reference
A cost-effectiveness analysis of South Africa’s seasonal influenza vaccination programme
10.1016/j.vaccine.2020.11.028 · 2020 · External reference
Updated cost-effectiveness analysis of palivizumab (Synagis) for the prophylaxis of respiratory syncytial virus in infant populations in the UK
10.1080/13696998.2020.1836923 · 2020 · External reference
Agenda de Investigação em Saúde (AGISA), 2024 - 2028
2024 · External reference
GBD Results
2021 · External reference
Risk factors and circulation pattern of respiratory syncytial virus in children under 2 years in Maputo, Mozambique
2024 · External reference
Global Burden of Disease Study 2019 (GBD 2019) Disability Weights
2023 · External reference
Challenges and opportunities for respiratory syncytial virus vaccines
2013 · External reference
Supply catalogue
External reference
Handling fees
2024 · External reference
Potential impact and cost-effectiveness of injectable next-generation rotavirus vaccines in 137 LMICs: a modelling study
10.1080/21645515.2022.2040329 · 2024 · External reference
Cost of illness for childhood diarrhea in low- and middle-income countries: a systematic review of evidence and modelled estimates
10.1186/s12889-020-08595-8 · 2024 · External reference
Respiratory syncytial virus infection among children younger than 2 years admitted to a paediatric intensive care unit with extended severe acute respiratory infection in ten Gavi-eligible countries: the RSV GOLD—ICU Network study
10.1016/s2214-109x(24)00269-9 · 2024 · External reference
RSV Vaccine and mAb Snapshot
2023 · External reference
Highlights from the Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization 23-26 September 2024
2024 · External reference
Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants
10.1056/nejmoa2216480 · 2023 · External reference
Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants
10.1056/nejmc2214773 · 2023 · External reference
